6,7-二甲氧基-2-(甲硫基)萘 | 33212-93-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6,7-二甲氧基-2-(甲硫基)萘
• 英文名称: 6,7-dimethoxy-2-(methylthio)naphthalene
• 英文别名: 2,3-Dimethoxy-6-methylthionaphthalen；2,3-Dimethoxy-6-methylthionaphthalin；2,3-Dimethoxy-6-methylsulfanylnaphthalene
• CAS: 33212-93-0
• 化学式: C₁₃H₁₄O₂S
• 分子量: 234.319
• InChiKey: DXINKCCVZQOXMX-UHFFFAOYSA-N

物化性质

• 沸点：
  367.5±22.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  43.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲醇 、 6,7-二甲氧基-2-(甲硫基)萘 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以88.6%的产率得到(6,7-dihydroxy-2-naphthalenyl)dimethylsulfonium bromide
  参考文献：
  名称：

  Dopaminergic agonists: comparative actions of amine and sulfonium analogs of dopamine

  摘要：

  We have investigated the possibility that structural modifications of the sulfonium analogue of dopamine (4) would produce the same pattern of biological activity as structural modifications of dopamine. A series of methyl- tetralinyl -, and naphthalenylsulfonium analogues 5-7 were prepared and tested for their ability to inhibit the potassium-evoked release of [3H]acetylcholine from striatal slices. All compounds were tested under normal conditions and after depletion of dopamine stores with reserpine and alpha-methyl-p-tyrosine. The amine and sulfonium analogues 2-6 all showed direct agonist activity. The sulfonium analogue 7 produced, predominantly, indirect activity. In contrast to the amine analogues, chemical modifications of the sulfonium compounds produced little change in their dopamine agonist activity.

  DOI：

  10.1021/jm00371a021
• 作为产物：
  描述：

  1,2-二氢-6,7-二甲氧基萘 在 碳酸氢钠 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 0.34h， 生成 6,7-二甲氧基-2-(甲硫基)萘
  参考文献：
  名称：

  Dopaminergic agonists: comparative actions of amine and sulfonium analogs of dopamine

  摘要：

  We have investigated the possibility that structural modifications of the sulfonium analogue of dopamine (4) would produce the same pattern of biological activity as structural modifications of dopamine. A series of methyl- tetralinyl -, and naphthalenylsulfonium analogues 5-7 were prepared and tested for their ability to inhibit the potassium-evoked release of [3H]acetylcholine from striatal slices. All compounds were tested under normal conditions and after depletion of dopamine stores with reserpine and alpha-methyl-p-tyrosine. The amine and sulfonium analogues 2-6 all showed direct agonist activity. The sulfonium analogue 7 produced, predominantly, indirect activity. In contrast to the amine analogues, chemical modifications of the sulfonium compounds produced little change in their dopamine agonist activity.

  DOI：

  10.1021/jm00371a021

文献信息

• Cyclization of β-ketosulfoxide—III
  作者：Y. Oikawa、O. Yonemitsu

  DOI：10.1016/s0040-4020(01)97425-3

  日期：1974.1

  8-tetrahydronaphthalene (2) through an intramolecular nucleophilic substitution of a sulfonium ion intermediate (20b), while a β -ketosulfoxide having naphthalene nucleus (3) cyclized to a tetrahydrophenanthrene 4 via a Pummerer rearrangement product 23. Treatment of 1 with p-toluenesulfonic acid gave a mixture of 2,3,6-trisubstituted naphthalenes (7–10), whose composition was dependent on the reaction conditions

  与三氯乙酸或三氟乙酸一起加热时，2,4-二甲氧基苯乙基甲基亚磺酰基甲基酮（1）通过分子内环化为2,3-二甲氧基-5-甲硫基-6-氧代5、6、7、8-四氢萘（2）。 a离子中间体（20b）的亲核取代，而具有萘核（3）的β-酮亚砜通过Pummerer重排产物23环化成四氢菲4 。用对甲苯磺酸处理1得到2,3,6-三取代萘的混合物（7-10），其组成取决于反应条件。芳构化通过 2进行。
• Acid-catalysed formation of naphthalenes from a β-oxo-sulphoxide
  作者：Yuji Oikawa、Osamu Yonemitsu

  DOI：10.1039/c2971000555b

  日期：——

  Under mild conditions the β-oxo-sulphoxide (1) undergoes acid-catalyse rearrangement and cyclization to from naphthalenes.

  在温和的条件下，β-氧代亚砜（1）经历酸催化重排和环化成萘。
• [EN] 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS<br/>[FR] DÉRIVÉS DE 5-AMINO-2-PIPÉRIDINON-3-YL-1-OXOISOINDOLINE POUR LA DÉGRADATION DES AGENTS DE DÉGRADATION IKZF2
  申请人：HARVARD COLLEGE

  公开号：WO2021222542A1

  公开（公告）日：2021-11-04

  Provided herein are compounds that promote targeted degradation of IKZF2, a protein whose activity is implicated in the pathology of certain cancers (e.g., acute myeloid leukemia). Also provided are pharmaceutical compositions comprising the compounds. Also provided are methods of treating cancer, and methods of promoting the degradation of IKZF2 in a subject or biological sample by administering a compound or composition described herein.